Author Archives: Lu Rahman

#Drug discovery #Events #Protein misfolding

Wren Therapeutics & University of Florida at Targeting Protein Misfolding 2021

In the field of drug discovery, so called ‘undruggable’ targets are like the stubborn children of the protein world – notoriously difficult to find, and even harder to target. For undruggable protein misfolding diseases such as Alzheimer’s and Parkinson’s, traditional drug discovery and biological approaches have, to date, proved largely… Read More

#News

#Immunology / Virology & Vaccines #Life sciences #mRNA #Pharmaceutical

What the UK Budget means for the pharma sector: industry reaction

By Lu Rahman In his 2021 Budget, UK Chancellor of the Exchequer, Rishi Sunak, announced a range of measures designed to benefit UK science, business and technology. These included tax breaks for firms to designed to ‘unlock’ £20bn worth of business investment; incentives for companies to take on apprentices; allowing… Read More

#Editor's Choice #News #Trending News

#Drug development #Drug discovery #Gene therapy #Therapeutics

Geneticist launches Axovia Therapeutics to develop medicines for ciliopathies

Axovia Therapeutics, a gene therapy company developing disease-transformative medicines for ciliopathies, led by researcher Professor Philip Beales, has launched after being in stealth mode for the past year. Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, and is partially funded by UCL Technology Fund. Axovia is receiving initial operational… Read More

#Editor's Choice #News

#Covid-19 #Life sciences

Bruntwood SciTech acquires new science park in the Golden Triangle for £46.2m

Property provider Bruntwood SciTech, dedicated to the growth of the science and technological sector, has expanded into the “Golden Triangle” through the acquisition of Melbourn Science Park from independent technology and product development company TTP for £46.2 million. Bruntwood SciTech will work closely with the local planning authority to develop… Read More

#Editor's Choice #News

#Biopharmaceuticals #Covid-19 #Podcast #Therapeutics

How critical is the part therapeutics in the COVID-19 pandemic? – podcast

The latest DDW Sitting Down With podcast features Guy Goldberg, Chief Business Officer of RedHill Biopharma. RedHill Biopharma  is a biopharmaceutical company that recently announced the dosing of the first patient in its US Phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19… Read More

#Covid-19 #Editor's Choice #News

#Biotechnology #Cell and gene therapy #Pharmaceuticals

WuXi AppTec acquires OXGENE to strengthen cell and gene therapy service

WuXi AppTec, provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, has completed the acquisition of OXGENE, a UK-based contract research and development organisation that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the… Read More

#Editor's Choice #News

#AI #Biopharmaceuticals #Clinical trials

Phesi collaborates with Alfasigma on clinical development

Phesi, provider of AI-based clinical development analytics products and solutions, is showcasing its data-driven clinical development approach at SCOPE Virtual Summit for Clinical Operations Executives 2021, in a case study session with international pharmaceutical company, Alfasigma. Phesi and Alfasigma are currently working together to maximise the value of priority medical… Read More

#News

#Anti-virals #Covid-19 #Interferons #Therapeutics

Inventor of synthetic Interferon discusses potential against COVID-19

ILC Therapeutics, a biotech company based in Scotland, is developing a synthetic Interferon which has shown great promise against COVID-19 in laboratory testing and will enter clinical trials later this year. It will be, says the company, the first synthetic Interferon based on the most prominent activities of the natural… Read More

#Covid-19 #Editor's Choice #Exclusive Content #Opinion

#Antibodies #Nanobodies

ChromoTek and Absolute Antibody collaborate on recombinant antibodies

ChromoTek, part of Proteintech specialising in nanobody-based reagents, and Absolute Antibody, provider of recombinant antibody technology, have announced a partnership to offer recombinant engineered antibodies to scientists worldwide. The chimeric antibodies were originally derived from alpaca nanobodies and engineered onto mouse and rabbit Fc domains to open up new research… Read More

#News

#Big pharma #Medical devices #Pharmaceuticals

The rise of neurotech devices and the moment of truth for the pharma industry

by Tiago R. Felix Simply put, drugs alone are not, and will probably not be, an effective and safe treatment for most cases of nervous system disorders (NSDs). However, both society and the pharmaceutical industry seem to have so far largely overlooked the most promising alternative to drugs in the… Read More

#News

#Antibodies #Biotechnology

Exclusive: The man behind the next generation antibody discovery platform

Last year IONTAS, a biotechnology company focused on antibody discovery and development, entered into a licensing agreement with Bristol Myers Squibb for its proprietary mammalian display. John McCafferty, nuclease directed mammalian display inventor and co-inventor of antibody phage display, told Lu Rahman about this breakthrough work. The company operates as… Read More

#Exclusive Content #News #Opinion

#Events #Lab automation

SLAS Europe 2021 Hybrid taking place in June

SLAS Europe 2021 Hybrid will take place on 22-25 June in Vienna and online. The event will include short courses which will take place on 22 June, followed by a two-day exhibition on 23-24 June. There will also be three days of scientific sessions from 23-25 June. Other features include… Read More

#News

#AI / data analytics / healthtech / informatics #Chromatography #Drug discovery

Waters and TetraScience partner to deliver access and insights for chromatography data

Waters Corporation has entered a reseller agreement with TetraScience, a cloud technology innovator for life sciences R&D. Through the partnership, Waters will offer its customers the Empower Data Science Link, powered by TetraScience. This technology pairs Waters’ compliance-ready Empower Chromatography Data System (CDS) with TetraScience’s Data Platform and data science… Read More

#News

#Immuno-oncology #T-Cells #Therapeutics

T-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics

T-Cypher Bio, a biotech company pioneering a novel approach to (T cell receptor) TCR therapeutics has separated from Orbit Discovery to focus on developing a functional, high-throughput, bead-display platform to select therapeutically relevant targets and identify potent, target-specific TCRs for the treatment of solid tumours and other indications. The formation… Read More

#News